AD-214 Phase I HV SAD top-line results Claudia Gregorio-King, AdAlta Investor Briefing Mar 10, 2021

(12:7)

AdAlta says new AD-214 dosing models enhance partnering potential

(3:45)

AdAlta (ASX: 1AD) AD-214 strategy webinar : 19 July 2021

(44:54)

AdAlta completes enrolment for AD-214 fibrosis safety trial

(3:)

AdAlta CEO highlights strong progress across CAR-T and AD-214 programs

(3:20)

AdAlta to support early return to clinical trials of AD-214 with rights offer

(3:46)

AdAlta secures A$1.28 million in rights offer to advance AD-214

(3:)

AdAlta Special Investor Briefing - Sam Cobb - Update on AD-214

(19:50)

AdAlta Special Investor Briefing - Dr Dallas Hartman - Manufacturing of AD-214

(27:50)

AdAlta eyes AD-214 Phase I extension study

(3:15)

AdAlta back in the clinic with AD-214

(3:)

AdAlta delivers positive Phase I Extension Study results for AD-214

(5:54)

AdAlta makes significant progress in expanding value of AD-214

(4:15)

AdAlta secures Chinese permit for AD-214

(5:19)

AdAlta links AD-214 results with efficacy thanks to new data

(4:16)

AD 214 Phase 1 clinical strategy, Investor Briefing March 3, 2020

(11:27)

AdAlta talks pre-clinical progress, Indian patent for AD-214

(6:54)

AD 214 pre-clinical update and PET tracer Investor Briefing March 3, 2020

(12:44)

AdAlta's AD-214 pre-clinical program progressing well

(5:)

AdAlta secures European patent for AD-214 and progresses partnering at BIO International Convention

(5:)